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1. Introduction 
During pregnancy, maternal-endocrine regulation, as well as all their physiology, undergoes 
profound adaptive changes in the framework of a functional organization structured in 
three interrelated compartments: the mother, placenta and fetus. Many of these changes are 
initially induced by estradiol and progesterone produced by the corpus luteum, combined 
with chorionic gonadotropin. As the pregnancy progresses, steroid and peptide hormones 
produced by the fetoplacental unit, took over. As a result of these adaptive phenomena is 
achieved adequate nutritional support of the fetus, uterine quiescence is maintained during 
childbirth, and breastfeeding is finally possible (Schindler, 2005). 
2. Cushing´s syndrome 
During normal pregnancy, serum cortisol increase gradually from the second quarter, 
keeping the circadian rhythm. Part of the increase in serum cortisol is due to increased 
estrógens and secondarily to increased cortisol binding protein (CBG), although serum free 
cortisol, urine and saliva can be elevated up to 2-3 times. The plasma concentration of 
ACTH is usually normal, although during pregnancy can be reduced or increased. There is a 
gradual increase in late pregnancy and during delivery (Lindsay & Nieman, 2005). The 
placenta during gestation can produce CRH which is released into the maternal circulation, 
although this may have implications in the regulation of ACTH and cortisol secretion are 
not well known. 
Cushing`s syndrome is uncommon during pregnancy, because hypercortisolism produces 
anovulation and infertility by altering androgenos and gonadotropin.  
The frecuency of ACTH-independent cases is increased in pregnant as compared to non 
pregnant individuals. Of the approximately 136 reported cases, approximately 60% had 
ACTH independent Cushing´s Syndrome: 44% adenoma y 11% carcinoma and the 
remainder a mix of primary pigmented nodular adrenal disease, ACTH independent 
hyperplasia and ectopic ACTH secretion. Five pregnant women with the ectopic ACTH 
syndrome have been reported (Guilhaume et al., 1992). 
The fetus is partially protected from the hypercortisolemia because placental 11-
betahydroxysteroid dehydrogenase converts 85% of maternal cortisol to biologically inactive 
cortisone. However, untreated Cushing´s syndrome has been associated with spontaneous 
abortion (25%), premature delivery (50%) and rarely, neonatal adrenal insufficiency (Aron et 
al., 1990). 
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Maternal complications also can occur. These include hypertension in nearly 70%, 
gestational diabetes in 25%, myopathy, opportunistic infections,  fractures, preeclampsia 
and rarely heart failure. Two maternal deaths have been reported (Vilar et al., 2007). 
2.1 Diagnosis 
The presence of Cushing´s Syndrome during pregnancy may be masked since some of the 
symptoms and signs of this disorder (weight gain, hypertension, striae) can also occur in 
normal pregnant women. Biochemical changes during normal pregnancy can interfere with 
the diagnosis: 
The normal pregnancy rises in ACTH and cortisol levels. The hypercortisolism of pregnancy 
continues to exhibit a normal circadian rhythm, though with a higher nighttime nadir; loss 
of diurnal rhythm is characteristic of all forms of Cushing syndrome. Salivary cortisol 
measurements may assist in determining this lack of diurnal response, but normal midnight 
levels have no been standardized for pregnancy. Urinary free cortisol levels greater than 3 
times the upper limit of normal may be interpreted as indicating Cushing´s syndrome in the 
second and third trimester. There are limited or no data using antibody based assays or 
mass spectrometry. Normal pregnancy is also associated with inadequate suppression of 
ACTH and cortisol during the overnight dexamethasone suppression test (Carr et al., 1981). 
ACTH levels may not reliably distinguish between pituitary and adrenal etiologies, as the 
levels may be normal or high in all form of Cushing syndrome, likely from placental ACTH 
production. When plasma ACTH levels are suppressed, preferably as measured using a 
two-site immunometric assay, no further biochemical testing is needed. 
The high dose dexamethasone suppression test will cause >80% suppression of serum 
cortisol in normal pregnancy. Patient with adrenal Cushing may be identified with this test 
as they don’t suppress, but the test may misclassify those with Cushing disease, as three of 
seven cases failed to suppress in small series (Lindsay et al., 2005). 
2.2 Differential diagnosis 
Because of the persistent elevations of ACTH in pregnancy, an ACTH suppressed is not 
always found in independent causes of Cushing syndrome. Thus, while its measurement 
may be useful, lack of suppressed value does not exclude and ACTH independent cause. 
There are limited data on the response to dexamethasone, 8 mg, of women with adrenal 
causes of Cushing´s syndrome and pituitary adenomas. In general, those with and adrenal 
etiology do not suppress, while those with Cushing disease do suppress serum cortisol. 
(Barasch et al., 1988). 
Because adrenal form of Cushing´s syndrome are common in pregnancy, it is reasonable to 
perform and adrenal ultrasound to look for a mass, as well as an ACTH level and 
dexamethasone suppression test as an initial evaluation. 
CRH stimulation test has been performed rarely in pregnant patients. Magnetic resonance 
(MRI) cannot be performed in the first trimester because of concerns about potential adverse 
fetal effects; during the remainder of gestation it is not commonly given with gadolinium 
contrast. 
2.3 Treatment 
Adrenal surgery has been performed at the 16 to 21 weeks of pregnancy without 
complicating the pregnancy (Buescher, 1996). It can be performed using a laparoscopic 
www.intechopen.com
 
Adrenal Disease and Pregnancy 
 
53 
approach. There is no clear evidence that early treatment is more beneficial than later 
treatment, this is likely because treatment is generally begun late. Early second trimester 
surgical treatment would be optimal. For women who do no want surgery or are diagnosed 
later, maternal hypercortisolism can be controlled with metyrapone. Metyrapone has side 
effects including hypertension and preeclampsia. (Blanco et al., 2006). Ketoconazol therapy 
is associated with intrauterine growth retardation, but no malformation or neonatal adrenal 
insufficienc (Berwaerts et al., 1999). Aminoglutethamide may cause fetal masculinization 
and mitotane is teratogenic; both should be avoided. 
Transsphenoidal surgery and pituitary radiation have both been used without complicating 
the pregnancy (Casson et al., 1987). 
Treating the Cushing´s syndrome does not reduce the frecuency of intrauterine growth 
restriction (about 30%) or premature birth (about 65%), but it does appear to prevent 
stillborn deliveries (about 10% with treatment) (Buescher, 1996). 
3. Adrenal insufficiency 
The adrenal insufficiency (AI) is rare, but early diagnosis is very important to improve 
maternal-fetal treatment. The primary AI or Addison's disease involves adrenal cortex atrophy 
with response insensitivity to ACTH and angiotensin 2, which causes a deficiency of 
glucocorticoids and aldosterone. The secondary and tertiary AI due to lack of ACTH or CRH 
are secondary to hypothalamic-pituitary diseases or chronic administration of exogenous 
corticosteroids. The secondary and tertiary AI are not associated with mineralocorticoid 
deficiency (Ambrosi et al., 2003). 
The prevalence of primary adrenal insufficiency in pregnancy is unknown, with a series 
from Norway suggesting an incidence of 1 in 3000 births from 1976 to 1987. The most 
common etiology for primary adrenal insufficiency is autoinmune adrenalitis, which may be 
associated with autoinmune polyglandular syndrome. Primary adrenal insufficiency from 
infections, bilateral metastatic disease, hemorraghe or infarction is uncommon. Secondary 
adrenal insufficiency, from pituitary neoplasm or glucocorticoid suppression of the 
hypothalamic-pituitary-adrenal axis is more common (Stechova, 2004). 
Gestation in patients with AI should be considered high-risk pregnancy (Lindsay & Nieman, 
2005). Maternal mortality is rare today, after the introduction of hydrocortisone in 1950, as 
well as improved diagnosis and early treatment. When AI is not diagnosed during 
pregnancy, may not have negative effects to mother or fetus, indicating the transplacental 
passage of maternal fetal glucocorticoids. In these cases, disease appears in the 
postpartum.When the disease is previously known, it is necessary to adjust the dose of 
corticosteroids in order to avoid a default adrenal crisis defect or undesirable effects of 
excess treatment as hypertension and preeclampsia. 
The prevalence of fetal mortality is unknown, although cases have been reported about 
intrauterine death, most undiagnosed in pregnant women. Intrauterine growth retardation 
and low birth weight are the most frequent effects in untreated mothers.The concomitance 
between AI and other autoimmune diseases (DM, lupus, anticardiolipin antibodies) increases 
maternal-fetal morbidity. 
3.1 Diagnosis 
Most cases are diagnosed before pregnancy. 
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Adrenal insufficiency is associated with laboratory findings of hyponatremia, hyperkalemia, 
hypoglycemia, eosinophilia and lymphocytosis. Hiperkalemia may be absent, because of the 
pregnancy increase in the rennin angiotensin system (Gradden et al., 2001). Early morning 
plasma cortisol levels of <3.0 mcg/dl confirms AI, while a cortisol >19 mcg/dl in the first or 
early second trimester excludes the diagnosis in a clinically stable patient. Plasma cortisol 
levels may fall in the normal “nonpregnant” range due to increase in CBG concentrations in 
the second and third trimesters, but will not be appropriately elevated for the stage of 
pregnancy. Appropriate pregnancy-specific cutoffs for diagnosis with the standard 
cosyntropin test using 250 mcg dose have not been established. Plasma cortisol levels were 
60% to 80% above nonpregnant responses in normal pregnant women tested in the second 
and third trimesters in one series (Nolten et al., 1978). 
McKenna et al (McKenna et al., 2000) examined the 1 mcg low dose cosyntropin test for 
diagnosis of secondary adrenal insufficiency in women at 24-34 weeks gestational age, and 
found high sensitivity of diagnosis using a cutoff of 30 mcg/dl. Accuracy of dosing is more 
difficult with this than with the standard cosyntropin test. The cosyntropin test is less 
sensitive to detect early secondary or tertiary forms of adrenal insufficiency. Cortisol and 
ACTH responses to CRH are blunted in pregnancy, making the CRH stimulation test 
unreliable for differentiating secondary and tertiary adrenal insufficiency in pregnancy. 
With primary AI, ACTH levels will be elevated and a level above 100 pg/ml is consistent 
with the diagnosis. However, ACTH will not be low with secondary forms because of the 
placental production of this hormone, which is nevertheless insufficient to maintain normal 
maternal adrenal function. ACTH values fluctuate widely, and a single value is insufficient 
for diagnosis. Adrenal antibodies may assist in confirming idiopathic adrenal insufficiency, 
as approximately 90% of patients will have 21 hydroxylase antibodies and 30% will have 
antibodies to 17-hydroxylase and side-chain cleavage enzymes. Aldosterone to renin ratios 
are low with elevated plasma rennin activity in patient with mineralocorticoid deficiency 
from adrenal atrophy (Symonds & Craven, 1978). 
3.2 Treatment 
Patients with AI should be managed during pregnancy and childbirth by a 
multidisciplinary team that includes endocrinologist, obstetrician and  an expert 
neurosurgeon. 
3.2.1 Glucocorticoids 
The aim is to achieve a physiological replacement dose for optimal maternal and fetal 
monitoring. 
The most important period is the first trimester, because the symptoms may go unnoticed 
by the emesis of pregnancy and childbirth stress. Hydrocortisone is the glucocorticoid of 
choice at doses of 12-15 mg/m2 in 2 divided doses at breakfast and 1 / 3 at lunch. It is rare 
to increase the dose during pregnancy. 
Women must be educated on the need for treatment with parenteral hydrocortisone in cases 
of nausea, vomiting or intercurrent systemic disease. Prednisone or prednisolone should be 
avoided because Hydrocortisone is more physiological. 
3.2.2 Mineralocorticoids 
They are only required in primary AI. The most widely used on the single dose is 
fluorocortisona 9α ( 0.05 to 0.2 mg/day). The dose is stable during pregnancy, and it can be 
reduced in the third trimester if there are edemas or hypertension. 
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3.2.3 Adrenal crisis 
It may appear at any time if the AI is not diagnosed, but it is more often during the delivery, 
when there is infection, preeclampsia or hemorrhage.Treatment should be started with 
hydrocortisone intravenous (bolus of 100 or 200mg and then 50-100 mg every 6-8 hours). In 
women with hypoglycemia, it is necessary to administer dextrose.  
After stabilization, return to oral treatment. It is not necessary to administer 
Mineralocorticoids in the acute phase. During delivery, the dose of glucocorticoids should 
be doubled at onset of labor or to administer 50 mg of intravenous hydrocortisone. In case of 
caesarean, it is necessary to start treatment with hydrocortisone, 100 mg IV every 8 hours. 
The oral treatment must be restarted within 48 hours. 
After delivery, all women must maintain treatment with corticosteroids and with dosis of 
mineralocorticoids similar to the prepregnancy period. 
It is not necessary to follow hypothalamic-pituitary axis in children of mothers with AI if 
they have been well treated during pregnancy. It can be necessary in mothers who have 
received supraphysiological doses. 
The replacement therapy can continue during lactation. It is excreted 0.5% per liter of milk 
of the absorbed dose (Sidhu & Hawkins, 1981). 
4. Primary hyperaldosteronism 
Primary hyperaldosteronism rarely has been reported in pregnancy and is most often 
caused by an adrenal adenoma (Okawa et al., 2002). There are reports of glucocorticoid 
remediable hyperaldosteronism in pregnancy (Wyckoff et al., 2000). The elevated 
aldosterone levels found in patients are similar to those in normal pregnant women, but the 
plasma rennin activity is suppressed. Moderate to severe hypertension is seen in 85%, 
proteinuria in 52% and hypokalemia in 55%, and symptoms may include headache, malaise, 
and muscle cramps. Placental abruption and preterm delivery are risks. Progesterone has an 
antimineralocorticoid effect at the renal tubules, and the hypertension and hypokalemia 
may ameliorate during pregnancy (Matsumoto et al., 2000). 
The physiologic rise in aldosterone during pregnancy overlaps the levels seen in primary 
aldosteronism, making diagnosis difficult. Suppressed rennin in the setting of 
hyperaldosteronism, is diagnostic. Salt loading test may be used to diagnose 
hyperaldosteronism, but there are potential fetal risks and no normative data. If baseline and 
suppression testing are equivocal, or radiological scanning does not suggest unilateral disease, 
patients may be treated medically until delivery to allow more definitive investigations. 
Spironolactone, the usual nonpregnant therapy, is contraindicated in pregnancy as it cross the 
placenta and is a potent antiandrogenic which can cause ambiguous genitalia in a male fetus. 
There is no published experienced with the use during pregnancy of eplerenone, the new 
aldosterone receptor antagonist. Surgical therapy may be delayed until postpartum if 
hypertension can be controlled with agents safe in pregnancy, such as amiloride, methyldopa, 
labetolol, and calcium channel blockers. Potassium supplementation may be required, but as 
noted above, the hypokalemia may ameliorate in pregnancy because of the antikaliuretic effect 
of progesterone. Both hypertension and hypokalemia may exacerbate postpartum due to 
removal of the progesterone effect ( Nursan et al., 2009). 
5. Pheochromocytoma 
Pheochromocytoma is a rare cause of hypertension during pregnancy, with clinical features 
similar to those in the general population (Keely, 1998). The prevalence is estimated at 1 in 
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54000 pregnancies (Botchan et al, 1995). As the uterus enlarges and an actively moving fetus 
compresses the neoplasm, maternal complications such as severe hypertension, hemorraghe 
into the neoplasm, hemodynamic collapse, myocardial infarction, cardiac arrhythmias, 
congestive heart failure, and cerebral hemorraghe may occur. Extra-adrenal tumours which 
occur in 10%, such as in the organ of Zuckerkandl at the aortic bifurcation, are particularly 
prone to hypertensive episodes with changes in position, uterine contractions, fetal 
movement, and Valsalva maneuvers. Unrecognized pheochromocytoma is associated with a 
maternal mortality rate of 50% at induction of anesthesia or during labor (Lau et al., 1996). 
There is a minimal placental transfer of catecholamines likely due to high placental 
concentrations of catechol-O-methyltransferase and monoamine oxidase. Adverse fetal 
effects such hypoxia are a result of catecholamine-induced uteroplacental vasoconstriction 
and placental insufficiency, and of maternal hypertension, hypotension, or vascular collapse 
(Saarikoski, 1974). 
5.1 Diagnosis 
Diagnosis of pheochromocytoma requires a high index of suspicion. Preconception 
screening of families known to have MEN 2 with RET proto-oncogene is essential. The 
diagnosis should be considered in pregnant women with severe or paroxysmal 
hypertension, particularly in the first half of pregnancy or in association with orthostatic 
hypotension or episodic symptoms of pallor, anxiety, headaches, palpitations, chest pain, or 
diaphoresis. Symptoms may occur or worsen during pregnancy because of the increased 
vascularity of the tumour and mechanical factors such as pressure from the expanding 
uterus or fetal movement (Harper et al, 1989). As in nonpregnant women, the diagnosis is 
usually based upon the results of 24-hour urinary fractionated metanephrines and 
catecholamines and plasma fractionated metanephrines. If possible, methyldopa and 
labetolol should be discontinued prior to the investigation as these agents may interfere 
with the quantification of the catecholamines. MRI is the imaging test of choice in the 
pregnant women. Stimulation test and 123-I-MIBG scintigraphy are not considered safe for 
pregnant women. 
5.2 Treatment 
Medical therapy should be iniciated with alpha adrenergic blockade (usually 
phenoxybenzamine) (Stenstrm & Swolin , 1985). 
 Ii is started at a dose of 10 mg twice daily, with titration until the hypertension is controlled. 
Placental transfer of phenoxybenzamine occurs, but is generally safe (Santeiro et al., 1996). 
Beta blockade is reserved for treating maternal tachycardia of arrhythmias which persist 
after full alpha blockade and volume repletion. 
Beta blockers may be associated with fetal bradycardia and with intrauterine growth 
retardation, when used early in pregnancy (Chatterjee & Parekh , 1985) All of these 
potential fetal risks are small compared to the risk of fetal wastage from unblocked high 
maternal levels of catecholamines. Hypertensive emergencies should be treated with 
phentolamine or nitroprusside, although the latter should be limited because of fetal 
cyanide toxicity. 
The timing of surgical excision of the neoplasm is controversial. In the first half of 
pregnancy, surgical excision may proceed once adequate alpha-blockade is established, 
although there is a higher risk of miscarriage with first trimester surgery. In the early second 
trimester, abortion is less likely and the size of the uterus will nor make excision difficult. If 
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the pheochromocytoma is not recognized until the second half of gestation, increasing 
uterine size makes surgical exploration difficult (Sarathi et al,. 2010). 
Successful laparoscopic excision of a pheochromocytoma in the second trimester of 
pregnancy has been described (Finkensted et al, 1999). 
Other options include combined cesarean delivery and tumour resection or delivery 
followed by tumour resection at a later date. Delivery is generally delayed until the fetus 
reaches sufficient maturity to reduce postpartum morbidity, providing successful medical 
management exists. Although successful vaginal delivery has been reported, it has been 
associated with higher rates of maternal mortality than caesarean section (Schenker & 
Granat, 1982). 
6. Congenital Adrenal Hyperplasia (CAH) 
It occurs in a family of monogenic inherited enzymatic defects of adrenal steroid 
biosynthesis, with manifestations secondary to an accumulation of precursors proximal to 
the enzymatic deficiency. The most common form of CAH is 21-hydroxylase deficiency, 
seen in more than 90% of the CAH cases in pregnancy (Forest, 2004). 
Classic, severe 21-hydroxylase deficiency is associated with ambiguous genitalia, and 
inadequate vaginal introitis, and progressive postnatal virilization including precocious 
adrenarche, advanced somatic development, central precocious puberty, menstrual 
irregularity , a reduced fertility rate, and possible salt wasting (White & Speiser, 2000). 
The spontaneous abortion rate is twice that in the normal population, and congenital 
anomalies are more frecuent. Conception requires adecuate glucocorticoid therapy, which 
then continues at stables rates during gestation, except at labor and delivery. Nonclassical 
21-hydroxilase deficiency patients present with pubertal and postpubertal hirsutism and 
menstrual irregularity, and may have improved fertility with glucocorticoid therapy ( Krone 
et al., 2001). 
ACTH stimulation testing to measure 17-OH progesterone demonstrates overlap between 
heterozygotes for CAH and the normal population. Ideally CYP21 genotyping should be 
performed. Virilization is not seen in the female fetus with non classical 21-hydroxylase 
deficiency, but occurs in a fetus with classic 21-hydroxylae unless fetal adrenal androgen 
productions is adequately suppressed. 
Dexamethasone most readily crosses the placenta as it is not bound to CBG and is not 
metabolize at dose of 20 mcg/kg maternal body weight per day to a maximum of 1.5 mg 
daily in 3 divided doses beginning at recognition of pregnancy before the 9th week of 
gestation, though lower doses are recommended by some (Coleman MA, Honour, 2004). 
Maternal plasma and/or urinary estriol levels reflect fetal adrenal synthesis and are 
monitored to assess efficacy. Maternal cortisol a DHEA-S levels will represent maternal 
adrenal suppression. 
As only 25% of female fetuses are affected in a family with CAH, it is important to 
discontinue therapy as soon as possible in the male fetus and unaffected female fetus. 
 Chorionic villus sampling at 9-11 weeks gestation may be used for gender determination 
and direct ADN analysis for the 21-hydroxilase gene CYP21. 
Side effects of dexamethasone therapy are potentially significant, including excessive weight 
gain, sever striae with scarring, edema, irritability, gestational diabetes mellitus, 
hypertension, and gastrointestinal intolerance. In affected pregnancies, dexamethasone may 
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be lowered to 0.75 to 1 mg/day in the second half of pregnancy to decrease maternal side 
effects while avoiding fetal virilisation (Pang et al, 1990). 
7. Conclusion 
Pregnancy is a stage of life very important. It is important to recognize and to treat adrenal 
disease during pregnancy to avoid complications in the mother and fetus. 
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